FC
CLDI icon

Finepoint Capital’s Calidi Biotherapeutics CLDI Stock Holding History

Finepoint Capital’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$249 Hold
1,042
– – ﹤0.01% 9
2025
Q4 		$1.22K Hold
1,042
– – ﹤0.01% 9
2025
Q3 		$1.58K Hold
1,042
– – ﹤0.01% 9
2025
Q2 		$2.88K Hold
1,042
– – ﹤0.01% 10
2025
Q1 		$7.08K Hold
1,042
– – ﹤0.01% 25
2024
Q4 		$14.4K Hold
1,042
– – ﹤0.01% 26
2024
Q3 		$14.2K Hold
1,042
– – ﹤0.01% 25
2024
Q2 		$25K Hold
1,042
– – 0.01% 25
2024
Q1 		$70.6K Hold
1,042
– – 0.02% 20
2023
Q4 		$189K Hold
1,042
– – 0.06% 18
2023
Q3 		$416K Buy
+1,042
New +$1.05M 0.21% 17

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Finepoint Capital's CLDI Position: Q1 2026 in Review

Finepoint Capital held its Calidi Biotherapeutics (CLDI) position steady in Q1 2026 at 1,042 shares worth $249. The position accounts for ﹤0.01% of the portfolio, ranked #9.

Finepoint Capital first reported a position in CLDI in Q3 2023 and has held it in 11 quarters since. The position peaked at $416K in Q3 2023. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Finepoint Capital held 1,042 shares of Calidi Biotherapeutics worth $249 as of Q1 2026.
  • Finepoint Capital left its Calidi Biotherapeutics share count unchanged in Q1 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of Finepoint Capital's portfolio in Q1 2026, its #9 holding.
  • Finepoint Capital first reported a position in Calidi Biotherapeutics in Q3 2023 and has held it in 11 quarters since.
  • Finepoint Capital's Calidi Biotherapeutics position peaked at $416K in Q3 2023.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Finepoint Capital's 13F filing for Q1 2026, filed 14 May 2026.